MNX.V - Manitex Capital Inc.

TSXV - TSXV Delayed Price. Currency in CAD

Manitex Capital Inc.

16667 Hymus Boulevard
Kirkland, QC H9H 4R9

IndustryMedical Distribution
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Steven SaviukChairman, Pres & CEO392.5kN/A1959
Ms. Helen SaviukCFO & Director200.46kN/AN/A
Mr. Ronald S. Perry CA, CPASec. & Independent DirectorN/AN/A1956
Mr. Marc LegerExec. VP of Commercial Operations - Valeo Pharma Inc180.32kN/AN/A
Nathalie TherrienVice-Pres of QA & Regulatory Affairs - Valeo Pharma Inc.170.08kN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Manitex Capital Inc., through its subsidiary, Valeo Pharma Inc., acquires and markets specialty pharmaceutical products, and distributes third-party pharmaceutical products primarily in Canada. It operates through two segments, Investments and Pharmaceutical. The company sells its products through wholesalers and retail pharmacy chains, as well as through hospitals and other groups. It also invests in marketable securities, as well as provides consulting services for private companies. Manitex Capital Inc. is headquartered in Kirkland, Canada.

Corporate Governance

Manitex Capital Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.